drugset / Trial / NCT05001984

Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis

NCT05001984

Phase 2 Active not recruiting 60 enrolled Chang Gung Memorial Hospital Chang Gung University · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate whether low-density lipoprotein (LDL-C) lowering with alirocumab results in greater change from baseline in intracranial atherosclerotic plaque at week 26 than control in adults with acute ischemic stroke from intracranial atherosclerosis taking lipid lowering therapy.

Timeline

Start
2021-08-01
Primary completion
2025-04-15
Completion
2025-04-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alirocumab Monoclonal antibody 75 mg Subcutaneous